Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Lexeo Therapeutics (Nasdaq: LXEO), a clinical stage genetic medicine company focusing on genetically defined cardiovascular diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. R. Nolan Townsend, the company's CEO, will deliver a presentation on Wednesday, January 15, 2025 at 8:15 AM PT in San Francisco, California.
The presentation will be accessible through a live webcast in the News & Events tab of the Investors section on the company's website. A replay option will be made available following the presentation for those unable to attend the live session.
Lexeo Therapeutics (Nasdaq: LXEO), una società di medicina genetica in fase clinica che si concentra su malattie cardiovascolari geneticamente definite, ha annunciato la sua partecipazione al 43° Annuale J.P. Morgan Healthcare Conference. R. Nolan Townsend, CEO dell'azienda, terrà una presentazione mercoledì 15 gennaio 2025 alle 8:15 AM PT a San Francisco, California.
La presentazione sarà accessibile tramite una diretta streaming nella sezione Notizie e Eventi della parte Investors del sito web dell'azienda. Sarà disponibile anche un'opzione di riproduzione per coloro che non potranno partecipare alla sessione dal vivo.
Lexeo Therapeutics (Nasdaq: LXEO), una empresa de medicina genética en etapa clínica centrada en enfermedades cardiovasculares definidas genéticamente, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. R. Nolan Townsend, el CEO de la compañía, realizará una presentación el miércoles 15 de enero de 2025 a las 8:15 AM PT en San Francisco, California.
La presentación será accesible a través de una transmisión en vivo en la pestaña de Noticias y Eventos de la sección de Inversores en el sitio web de la empresa. También se ofrecerá una opción de repetición para aquellos que no puedan asistir a la sesión en vivo.
Lexeo Therapeutics (Nasdaq: LXEO)는 유전적으로 정의된 심혈관 질환에 집중하는 임상 단계 유전자 치료 회사로, 제43회 연례 J.P. Morgan Healthcare Conference에 참여한다고 발표했습니다. R. Nolan Townsend CEO가 2025년 1월 15일 수요일 오전 8:15 PT에 캘리포니아 주 샌프란시스코에서 발표를 진행할 예정입니다.
발표는 회사 웹사이트의 투자자 섹션의 뉴스 및 이벤트 탭에서 라이브 웹캐스트를 통해 접속할 수 있습니다. 실시간 세션에 참석할 수 없는 분들을 위해 발표 후 다시 보기 옵션도 제공됩니다.
Lexeo Therapeutics (Nasdaq: LXEO), une entreprise de médecine génétique en phase clinique axée sur les maladies cardiovasculaires définies génétiquement, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. R. Nolan Townsend, le PDG de l'entreprise, présentera une communication le mercredi 15 janvier 2025 à 8h15 PT à San Francisco, Californie.
La présentation sera accessible par le biais d'une diffusion en direct dans l'onglet Actualités et Événements de la section Investisseurs sur le site web de l'entreprise. Une option de rediffusion sera également disponible après la présentation pour ceux qui ne peuvent pas assister à la session en direct.
Lexeo Therapeutics (Nasdaq: LXEO), ein klinisches Unternehmen für genetische Medizin, das sich auf genetisch definierte Herz-Kreislauf-Erkrankungen spezialisiert hat, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference angekündigt. R. Nolan Townsend, der CEO des Unternehmens, wird am Mittwoch, den 15. Januar 2025 um 8:15 Uhr PT in San Francisco, Kalifornien, eine Präsentation halten.
Die Präsentation wird über einen Live-Stream im Nachrichten- und Veranstaltungstabs des Investorenbereichs auf der Website des Unternehmens zugänglich sein. Eine Wiederholungsoption wird für diejenigen, die nicht an der Live-Sitzung teilnehmen können, nach der Präsentation verfügbar sein.
- None.
- None.
NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 8:15 AM PT in San Francisco, California.
The event will be webcast live under the News & Events tab in the Investors section of the Company’s website. A replay of the webcast will be available on the website following the presentation.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.
Media Response:
media@lexeotx.com
Investor Response:
Carlo Tanzi, Ph.D.
ctanzi@kendallir.com
FAQ
When is Lexeo Therapeutics (LXEO) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Lexeo Therapeutics' (LXEO) J.P. Morgan Healthcare Conference presentation?
What is the focus area of Lexeo Therapeutics (LXEO)?
Who will represent Lexeo Therapeutics (LXEO) at the 2025 J.P. Morgan Healthcare Conference?
